Physician profile
Paul Bader
NPI 1740281450
$14,982.73
in general payments reported to CMS, 2019-2025
64 companies · $1,978 in 2025
The $1,978 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,019 · 2020: $1,865 · 2021: $2,413 · 2022: $2,416 · 2023: $2,239 · 2024: $2,051 · 2025: $1,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,082 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,082.09 |
| Education | $186.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,228.92 | 2019-2025 | |
| Janssen Biotech, INC. | $1,168.38 | 2019-2025 | Tecvayli, Darzalex, Erleada |
| Astrazeneca Pharmaceuticals Lp | $975.27 | 2019-2025 | Tagrisso, Lynparza, Imfinzi |
| Lilly USA, LLC | $778.32 | 2019-2025 | Verzenio, Retevmo, Jaypirca |
| Amgen INC. | $720.79 | 2019-2025 | Lumakras, Uplizna |
| E.R. Squibb & Sons, L.L.C. | $711.15 | 2019-2025 | Opdivo, Reblozyl |
| Novartis Pharmaceuticals Corporation | $688.40 | 2019-2025 | |
| Puma Biotechnology, INC. | $576.69 | 2019-2025 | Nerlynx |
| Taiho Oncology, INC. | $562.43 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $514.08 | 2019-2024 | |
| Incyte Corporation | $502.48 | 2019-2025 | Jakafi |
| Genzyme Corporation | $462.43 | 2019-2025 | |
| Glaxosmithkline, LLC. | $458.91 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Eisai INC. | $426.88 | 2020-2025 | |
| Celgene Corporation | $409.56 | 2019-2024 | Reblozyl, Opdualag, Pomalyst |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $368.41 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Array Biopharma INC | $356.51 | 2020-2025 | Braftovi, Mektovi, Tukysa |
| Sobi, INC | $343.16 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $325.58 | 2023-2025 | Orgovyx |
| Foundation Medicine, INC. | $316.16 | 2020-2023 | |
| Astellas Pharma US INC | $240.63 | 2019-2024 | Xtandi |
| Seagen INC. | $209.36 | 2020-2023 | Tukysa |
| Rigel Pharmaceuticals, INC. | $188.35 | 2021-2023 | Rezlidhia, Tavalisse |
| Myovant Sciences INC. | $186.35 | 2021-2022 | |
| Abbott Laboratories | $161.09 | 2025 | Esprit |
| Daiichi Sankyo INC. | $151.47 | 2019-2024 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $134.47 | 2019-2024 | Ninlaro |
| Pharmaessentia USA Corporation | $127.03 | 2023-2025 | Besremi |
| Genmab U.S., INC. | $122.95 | 2023-2024 | Tivdak, Epkinly |
| Genentech USA, INC. | $116.64 | 2019-2025 | Itovebi, Polivy |
| Pharmacyclics LLC, An Abbvie Company | $108.72 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $85.77 | 2024-2025 | Ultomiris |
| Epizyme, INC. | $85.39 | 2020-2022 | |
| Tesaro, INC. | $78.95 | 2019 | |
| Abbvie INC. | $77.18 | 2021-2025 | Venclexta |
| Agios Pharmaceuticals, INC. | $70.46 | 2023-2025 | Pyrukynd |
| Mirati Therapeutics, INC. | $67.58 | 2023-2024 | Krazati |
| Dova Pharmaceuticals | $67.57 | 2020-2021 | |
| Emd Serono, INC. | $65.72 | 2019 | |
| Clovis Oncology, INC. | $59.99 | 2019 | |
| Global Blood Therapeutics, INC. | $59.31 | 2020-2022 | |
| Kyowa Kirin, INC. | $51.91 | 2022-2025 | |
| Stemline Therapeutics INC. | $46.51 | 2024-2025 | Orserdu |
| Kite Pharma, INC. | $42.09 | 2020-2023 | Yescarta |
| Acceleron Pharma, INC. | $41.24 | 2020-2021 | |
| Springworks Therapeutics, INC. | $38.86 | 2024 | Ogsiveo |
| Verity Pharmaceuticals INC. | $36.07 | 2024 | Trelstar |
| Regeneron Healthcare Solutions, INC. | $30.07 | 2025 | Libtayo |
| Tg Therapeutics, INC. | $24.98 | 2022 | |
| Jazz Pharmaceuticals INC. | $24.52 | 2020 | |
| Gilead Sciences, INC. | $24.30 | 2022 | |
| Shield Therapeutics INC | $23.20 | 2024 | |
| Caris Mpi, INC. | $23.19 | 2025 | Mi Cancer Seek |
| Grifols USA, LLC | $22.67 | 2019 | |
| Karyopharm Therapeutics INC. | $22.44 | 2024 | Xpovio |
| Acrotech Biopharma INC. | $22.11 | 2024 | Beleodaq |
| Blueprint Medicines Corporation | $21.97 | 2020 | |
| Pharmacosmos Therapeutics INC. | $21.55 | 2024 | Cosela |
| Apellis Pharmaceuticals, INC. | $19.88 | 2022 | |
| Csl Behring | $18.94 | 2024 | Hizentra |
| Verastem, INC. | $18.79 | 2019 | |
| Geron Corporation | $18.72 | 2025 | Rytelo |
| Janssen Pharmaceuticals, INC | $14.82 | 2019 | |
| Emmaus Medical, INC. | $14.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Bader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.